Suppr超能文献

当前关于肠道微生物组与慢性荨麻疹的认识:发病机制方面的进展与新型治疗方法的机遇。

Current insights on gut microbiome and chronic urticaria: progress in the pathogenesis and opportunities for novel therapeutic approaches.

机构信息

West China School of Medicine, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, Sichuan, China.

出版信息

Gut Microbes. 2024 Jan-Dec;16(1):2382774. doi: 10.1080/19490976.2024.2382774. Epub 2024 Jul 30.

Abstract

Chronic urticaria (CU) is a prevalent skin disorder greatly impacting the patients' life quality, in which immune dysregulation mediated by gut microbiome plays a significant role. Several studies have found the gut dysbiosis exists in patients with CU. In addition, infection may also be one of the causes of CU. The primary treatment currently used for CU is the second-generation non-sedating H1-antihistamines (nsAH). However, there are some limitations in current therapies. Based on the latest evidence, this review provides an updated overview of how the gut dysbiosis influences CU development, explores potential therapeutic approaches based on the gut microbiota and summarizes the interaction between gut microbiota and current treatment.

摘要

慢性荨麻疹(CU)是一种常见的皮肤疾病,极大地影响了患者的生活质量,其中肠道微生物组介导的免疫失调起着重要作用。几项研究发现,CU 患者存在肠道菌群失调。此外,感染也可能是 CU 的原因之一。目前 CU 的主要治疗方法是第二代非镇静 H1 抗组胺药(nsAH)。然而,目前的治疗方法存在一些局限性。基于最新的证据,本综述提供了一个关于肠道菌群失调如何影响 CU 发展的最新概述,探讨了基于肠道微生物组的潜在治疗方法,并总结了肠道微生物组与目前治疗方法的相互作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/08a6/11290762/d3dcd939b0f9/KGMI_A_2382774_F0001_OC.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验